BRIEF REPORT
Open Access

Treatment of community-onset pneumonia in neutropenic cancer patients: β-lactam monotherapy versus combination antibiotic regimens

Hyeri Seok1,2†, Jae-Hoon Ko2†, Kyong Ran Peck2*, Ji-Yeon Kim2, Ji Hye Lee2, Ga Eun Park2, Sun Young Cho2, Cheol-In Kang2, Nam Yong Lee3 and Doo Ryeon Chung2

Abstract

Background: Although β-lactam monotherapy may be sufficient in non-critically ill patients with community-acquired pneumonia, the value of combination antibiotic regimens in community-onset neutropenic pneumonia remains unclear.

Methods: A retrospective cohort study was conducted to compare the effects of combination antibiotic regimens to those of β-lactam monotherapy in cancer patients with community-onset neutropenic pneumonia. Electronic medical records of patients diagnosed with community-onset neutropenic pneumonia between March 1995 and February 2015 at a tertiary care center were reviewed.

Results: During the study period, 165 cancer patients with community-onset neutropenic pneumonia were identified. Seventy-two patients received β-lactam monotherapy and 93 received combination therapy (β-lactam plus either a macrolide or fluoroquinolone). Causative pathogens were identified in 27.9% of the patients, and only two were positive for atypical pathogens. Although 30-day mortality was higher in the β-lactam group (15.3% versus 4.3%; \(P = 0.015\)), combination therapy was not associated with a statistically significant survival benefit in the multivariate analysis (hazard ratio 0.85, 95% confidence interval 0.20–3.67; \(P = 0.827\)). Duration of neutropenia, C-reactive protein level, and Multinational Association for Supportive Care in Cancer risk index were significant factors for 30-day mortality. In a subgroup analysis of patients treated with cefepime, the most frequently used β-lactam (63.0%), combination therapy also showed no significant survival benefit.

Conclusions: Combination antibiotic regimens were not associated with a survival benefit over β-lactam monotherapy in the treatment of community-onset neutropenic pneumonia. Unnecessary combination therapy should be reconsidered in cancer patients who are at high risk for adverse drug reactions and colonization with multidrug-resistant organisms.

Keywords: Febrile neutropenia, Pneumonia, Cancer, Combination antibiotic regimens
Background
Febrile neutropenia, an inevitable side effect of chemotherapy, contributes to high mortality among cancer patients [1]. Among various clinical presentations of febrile neutropenia, pneumonia is considered high-risk [2]. Guidelines do not specify empirical antibiotics for the treatment of neutropenic pneumonia, i.e. community-onset pneumonia with febrile neutropenia. Although the European Society for Medical Oncology guidelines recommend coverage of atypical pathogens by adding macrolide antibiotics in managing neutropic pneumonia, the level of evidence and grade of recommendation are very low [3]. Most clinicians choose a combination of an antipseudomonal β-lactam with azithromycin or fluoroquinolone targeting neutropic fever and community-acquired pneumonia (CAP). However, the indiscriminate use of macrolide or fluoroquinolone in cancer patients receiving chemotherapy may result in unexpected side effects such as cardiovascular events and acquisition of resistance [4–7]. This study aimed to answer the question of whether combination therapy is necessary in patients with neutropic pneumonia.

In the case of CAP, there has been already controversy about whether to start combination therapy as empirical antibiotics. The addition of macrolide or fluoroquinolone is based on the treatment for an atypical pathogen, antibiotic synergism, and anti-inflammatory effect. However, several studies have shown that β-lactam monotherapy is non-inferior to combination therapy [8–10]. Some have suggested that monotherapy may be considered in patients with low-risk CAP [11, 12]. Likewise, questions may arise as to whether combination therapy should be considered when neutropenic pneumonia is diagnosed in cancer patients who are receiving chemotherapy but with good performance status. To further investigate this question, we compared the effects of combination antibiotic regimens to those of β-lactam monotherapy in cancer patients with community-onset neutropenic pneumonia who were managed at a tertiary care center during a 20-year period.

Methods
Study design and population
A retrospective cohort study was conducted to compare the effects of combination antibiotic regimens to those of β-lactam monotherapy for the treatment of community-onset pneumonia in neutropic cancer patients. We reviewed the electronic medical records of individuals who were admitted and diagnosed with pneumonia between March 1995 and February 2015 at Samsung Medical Center, a 1950-bed tertiary care university hospital in Seoul, Republic of Korea. Adult (age ≥ 18 years) cancer patients who were diagnosed with community-onset neutropenic pneumonia during the study period were included in the analysis. We exclusively included chemotherapy-induced neutropenia in the present study, and underlying cancers included solid cancers, lymphoma, and multiple myeloma. Hematologic malignancies such as acute leukemia, aplastic anemia, or myelodysplastic syndrome that accompany prolonged neutropenia due to intensive chemotherapy or the nature of the disease, were excluded from the analysis because prolonged neutropenia, a strong prognostic factor of febrile neutropenia, may obscure the effect of antibiotics [1, 13, 14]. Patients with lymphoma and multiple myeloma who underwent bone marrow transplantation were also excluded for the same reason. The study population was divided into two groups according to antibiotic regimen. Patients who were re-admitted 7 days after discharge were excluded because they were assumed to have hospital-acquired pneumonia. The combination group included patients who were treated with a combination of a β-lactam and a macrolide or fluoroquinolone, and the β-lactam group included patients who received β-lactam therapy only. Additional use of other classes of antibiotics that do not have activity for atypical bacterial pathogens, such as aminoglycosides or vancomycin, was not considered when classifying study groups. The primary outcome was 30-day all-cause mortality, and secondary outcomes were 90-day all-cause mortality, length of hospital stay, and complications. The study protocol was approved by the Institutional Review Board of Samsung Medical Center.

Data collection
Retrospectively collected data included demographics, underlying diseases, clinical presentations and outcomes, laboratory test results, types and duration of antibiotic therapy, and microbiologic data. Microbiologic data included cultures of blood and respiratory specimens, pneumococcal and Legionella urinary antigen, influenza antigen, and mycoplasma antibody. The severity of neutropenic pneumonia was estimated using the CURB-65 score and the Multinational Association for Supportive Care in Cancer (MASCC) risk index [15, 16].

Definitions
Pneumonia was defined as the presence of parenchymal infiltration on chest radiography (newly appeared infiltration or aggravation of preexisting lesions) with relevant respiratory symptoms, including cough, sputum production, shortness of breath, or pleuritic chest pain [17]. Pneumonia was considered to be of community-onset if it developed in the community or within 48 h after hospital admission [17, 18]. Neutropenia was defined as an absolute neutrophil count < 500 cells/mm³ or an absolute neutrophil count expected to decrease to < 500 cells/mm³ during the next 48 h [2]. Fever was defined as body temperature ≥ 38.0 °C. The response to
Chemotherapy was evaluated according to the World Health Organization criteria or Response Evaluation Criteria in Solid Tumors guidelines [19–21]. The mycoplasma antibody test was considered positive if a single titer was highly elevated (≥1:320) or a four-fold increase in the titer was detected in a follow-up sample [22].

Statistical analyses
The sample size calculation for the study resulted in a sample size of 134 patients who were to be in a 1:1 allocation ratio to achieve a power of 95%. To compare the two groups, the Pearson χ² test and Fisher’s exact test were used for categorical variables, and Student’s t-test and the Mann-Whitney U test for continuous variables. The Cox proportional hazard model was used to examine the associations of the antibiotic regimens with 30- and 90-day mortality in neutropenic pneumonia after adjusting for potential confounding factors. All collected variables with any relevance to outcomes were evaluated by univariate analysis, and those with statistical significance were included in the multivariate analysis. All P-values were two-tailed, and those < 0.05 were considered to be statistically significant. All statistical analyses were performed using SPSS Statistics version 20.0 for Windows (IBM Corp., Armonk, NY, USA).

Results
Baseline characteristics, antibiotic types, severity, and cancer status of neutropenic pneumonia
During the study period, 165 cancer patients with community-onset neutropenic pneumonia were identified: 72 were classified in the β-lactam group and 93 in the combination group. Blood cultures were performed in 100% of the enrolled patients and cultures of lower respiratory specimens in 99.0% of the patients. Causative pathogens of neutropenic pneumonia were identified in 27.9% of the patients, of which Streptococcus pneumoniae was the most common followed by Pseudomonas aeruginosa, Staphylococcus aureus, and Klebsiella pneumoniae (23.9, 19.6, 15.2, and 13.0%, respectively; Additional file 1: Table S1). Serologic tests for Mycoplasma pneumoniae were conducted in 20 patients (12.1%), two of which yielded positive results. The urinary antigen tests for legionella were performed in 75 patients (45.5%), and all showed results. No patient received oral prophylactic antibiotics before the onset of neutropenic fever.

The baseline characteristics, types of antibiotics, and the severity of neutropenic pneumonia are presented in Table 1. Baseline characteristics were similar between the two groups, except for male predominance in the β-lactam group and a higher prevalence of chronic renal disease in the combination group. Ceftazidime was used more frequently in the β-lactam group, while piperacillin-tazobactam was used more in the combination group. Ceftazidime was administered with tobramycin for an initial 3–5 days, and 23.6% of the β-lactam group and 19.4% of the combination group used an initial vancomycin combination (P = 0.507). In the combination group, azithromycin was most frequently used for coverage of atypical pathogens, followed by levofloxacin, ciprofloxacin, and moxifloxacin (75.3, 11.8, 8.6, and 4.3%, respectively). The duration of antibiotic administration was similar between the two groups. Severity variables, including the presence of bacteremia, duration of neutropenia, C-reactive protein (CRP) level, CURB-65 score, and MASCC risk index were not statistically different between the two groups (all P > 0.05).

Types and status of cancers in patients with neutropenic pneumonia were not differently distributed between the two groups (Table 2, all P > 0.05). Lung cancer was the most common type of cancer, followed by lymphoma and breast cancer (44.8, 14.6, and 11.5%, respectively). Sixty-seven patients (40.6%) received chemotherapy for curative purposes, while the remainders (59.4%) were in palliative settings. Among patients in palliative settings, more than half (54.1%) experienced progression or relapse of underlying cancers despite previous chemotherapy.

Outcomes and complications of patients with neutropenic pneumonia
The outcomes and complications of patients with neutropenic pneumonia are summarized in Table 3. In the β-lactam group, 30-day (15.3% versus 4.3%, P = 0.015) and 90-day all-cause mortality (20.8% versus 7.5%, P = 0.013) were significantly higher. Length of hospital stay, pneumonia recurrence, and complications and adverse effects, including complicated pleural effusion, Clostridium difficile-associated colitis, and cardiac events, were similar between the two groups (all P > 0.05).

To identify potential confounding factors of 30-day all-cause mortality, all relevant variables were evaluated in a univariate fashion using the Cox proportional hazard model (Table 4). Underlying lung cancer, palliative setting, neutropenia duration, CRP level, MASCC risk index, combination therapy, and the usage of cefepime and carbapenem were statistically significant factors of 30-day all-cause mortality in the univariate analysis. In the multivariate analysis of these variables, combination therapy did not maintain a significant association (hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.20–3.67; P = 0.827). Duration of neutropenia (HR 1.27, 95% CI 1.05–1.53; P = 0.013), CRP level (HR 1.06, 95% CI 1.00–1.11; P = 0.021), and MASCC risk index (HR 0.80, 95% CI 0.65–0.99; P = 0.042) were persistent statistically significant factors of 30-day all-cause mortality. A multivariate analysis for 90-day all-cause mortality was performed.
(Additional file 2: Table S2). Combination therapy was not significantly associated with 90-day all-cause mortality (HR 0.67, 95% CI 0.23–2.76; \( P = 0.449 \)), while palliative setting of chemotherapy (HR 12.81, 95% CI 1.78–92.20; \( P = 0.011 \)), duration of neutropenia (HR 1.16, 95% CI 1.07–1.25; \( P = 0.011 \)), CRP level (HR 1.05, 95% CI 1.01–1.09; \( P = 0.020 \)), and MASCC index (HR 0.84, 95% CI 0.72–0.98; \( P = 0.024 \)) were statistically related to 90-day all-cause mortality.

Subgroup analysis of cefepime-treated patients with neutropenic pneumonia

Although we performed a multivariate analysis to adjust for potential confounding factors, the types of β-lactams were significantly unbalanced between the two groups. To verify the effect of combination therapy on all-cause mortality due to neutropenic pneumonia, we also performed a subgroup analysis controlling for β-lactam antibiotics, specifically cefepime which made up the highest proportion among the various β-lactams (63.0%). The same variables used in the analysis of the original cohort were included in the multivariate analyses for 30- and 90-day all-cause mortality. In the multivariate analyses of the cefepime-treated subgroup, combination therapy was not significantly associated with either 30-day (HR 0.76, 95% CI 0.06–9.18; \( P = 0.965 \)) or 90-day all-cause mortality (HR 0.78, 95% CI 0.18–3.45; \( P = 0.741 \)).

Discussion

This study showed that neither monotherapy nor combination therapy was associated with 30- and 90-day mortality in the treatment of neutropenic pneumonia. Although 30-day and 90-day all-cause mortality were higher in the β-lactam group than in the combination group before adjustment, this finding suggests that more patients in the β-lactam group had confounding factors for poor prognosis, including lung cancer, longer duration of neutropenia, or bacteremia, than patients in the combination group.

To our knowledge, this is the first study to compare the clinical efficacy of monotherapy and combination therapy in the treatment of neutropenic pneumonia, extending the concept of CAP. It has been already argued that

| Table 1 Baseline characteristics, types of β-lactams, and severity of patients with neutropenic pneumonia |
|------------------------------------------------------------------------------------------------|
| Variables                                      | β-lactam group (n = 72) | Combination group (n = 93) | \( P \)-value |
|------------------------------------------------|-------------------------|---------------------------|--------------|
| **Demographic data**                            |                         |                           |              |
| Age, years                                     | 61 ± 11                 | 62 ± 10                   | 0.296        |
| Male sex                                       | 59 (81.9%)              | 59 (63.4%)                | 0.009        |
| Smoking history                                | 29 (40.3%)              | 27 (29.0%)                | 0.130        |
| **Comorbid conditions**                        |                         |                           |              |
| Hypertension                                   | 14 (19.4%)              | 28 (30.1%)                | 0.119        |
| Diabetes mellitus                              | 5 (6.9%)                | 12 (12.9%)                | 0.212        |
| Cardiovascular diseases                        | 5 (6.9%)                | 2 (2.2%)                  | 0.130        |
| Chronic lung diseases                          | 3 (4.2%)                | 6 (6.5%)                  | 0.733        |
| Chronic liver diseases                         | 3 (4.2%)                | 3 (3.2%)                  | 1.000        |
| Chronic renal diseases                         | 0 (0.0%)                | 6 (6.5%)                  | 0.036        |
| **Types of β-lactams**                         |                         |                           |              |
| Cefepime                                       | 40 (55.6%)              | 64 (68.8%)                | 0.080        |
| Ceftazidime                                    | 20 (27.8%)              | 2 (2.2%)                  | < 0.001      |
| Piperacillin/tazobactam                        | 6 (8.3%)                | 21 (22.6%)                | 0.014        |
| Carbapenem                                     | 6 (8.3%)                | 6 (6.5%)                  | 0.644        |
| **Duration of antibiotic administration, days** | 12.4 (8.9–16.2)         | 11.7 (9.1–14.4)           | 0.646        |
| **Severity variables**                         |                         |                           |              |
| Presence of bacteremia                         | 16 (22.0%)              | 12 (12.9%)                | 0.114        |
| Duration of neutropenia, days                  | 1.5 (0.9–3.1)           | 1.4 (1.0–2.9)             | 0.773        |
| CRP, mg/dL                                     | 15.9 (6.5–24.0)         | 17.0 (6.4–25.9)           | 0.669        |
| CURB-65                                        | 1 (0–2)                 | 1 (0–2)                   | 0.898        |
| MASCC risk index                               | 16 (13–18)              | 16 (16–21)                | 0.059        |

Data are expressed as number (%) of patients, mean ± SD, or median (IQR)
aCeftazidime was administered with tobramycin for an initial 3–5 days

Abbreviations: CRP C-reactive protein, MASCC Multinational Association for Supportive Care in Cancer, SD Standard deviation, IQR interquartile range
monotherapy is sufficient for mild cases of CAP without neutropenia [11, 12]. The reasons for combination treatment is to cover atypical pathogens, antibiotics synergism, or anti-inflammatory effects. However, in fact, the proportion of atypical pathogens is known to be low in non-critically ill patients with CAP [8, 23]. A lack of synergistic effect between macrolide and β-lactam against *S. pneumoniae* has been described [24–26]. To date, no studies have shown the direct association between combination therapy and anti-inflammatory effect. Several studies have proven that β-lactam monotherapy is non-inferior to combination treatment [8–10, 26].

The concept that combination treatment may be unnecessary can be applied to neutropenic pneumonia.

### Table 2: Types and status of cancers in patients with neutropenic pneumonia

| Variables                  | β-lactam group (n = 72) | Combination group (n = 93) | P-value |
|----------------------------|-------------------------|----------------------------|---------|
| Type of cancer             |                         |                            |         |
| Head and neck              | 3 (4.2%)                | 1 (1.1%)                   | 0.319   |
| Lung                       | 36 (50.0%)              | 38 (40.9%)                 | 0.242   |
| Breast                     | 7 (9.7%)                | 12 (12.9%)                 | 0.526   |
| Esophageal and gastric      | 8 (11.1%)               | 6 (6.5%)                   | 0.287   |
| Colorectal                 | 1 (1.4%)                | 5 (5.4%)                   | 0.233   |
| Hepatobiliary and pancreatic | 0 (0.0%)               | 3 (3.2%)                   | 0.258   |
| Bladder                    | 1 (1.4%)                | 5 (5.4%)                   | 0.233   |
| Prostate                   | 0 (0.0%)                | 4 (4.3%)                   | 0.133   |
| Melanoma and sarcoma       | 1 (1.4%)                | 5 (5.4%)                   | 0.233   |
| Lymphoma and myeloma       | 15 (20.8%)              | 13 (14.0%)                 | 0.245   |
| Cancer status              |                         |                            |         |
| Curative setting           | 32 (44.4%)              | 35 (37.6%)                 | 0.377   |
| Neoadjuvant and adjuvant   | 12 (16.7%)              | 20 (21.5%)                 | 0.436   |
| Definitive                 | 20 (27.8%)              | 15 (16.1%)                 | 0.069   |
| Palliative setting         | 40 (55.6%)              | 58 (62.4%)                 | 0.377   |
| Complete response          | 1 (2.5%)                | 0 (0.0%)                   | 0.436   |
| Partial response           | 2 (5.0%)                | 4 (6.9%)                   | 0.697   |
| Stable disease             | 0 (0.0%)                | 4 (6.9%)                   | 0.133   |
| Progressed or relapse      | 22 (55%)                | 31 (53.4%)                 | 0.705   |
| Before evaluation          | 15 (37.5%)              | 19 (32.8%)                 | 0.949   |

Data are expressed as number (%) of patients

*aThe response to chemotherapy was evaluated according to the World Health Organization (WHO) criteria or Response Evaluation Criteria in Solid Tumors (RECIST) guidelines

### Table 3: Outcomes and complications of patients with neutropenic pneumonia

| Variables                          | β-lactam group (n = 72) | Combination group (n = 93) | P-value |
|------------------------------------|-------------------------|----------------------------|---------|
| 30-day all-cause mortality         | 11 (15.3%)              | 4 (4.3%)                   | 0.015   |
| 90-day all-cause mortality         | 15 (20.8%)              | 7 (7.5%)                   | 0.013   |
| Length of hospital stay, days      | 5.7 (4.4–10.9)          | 6.0 (4.3–8.6)              | 0.632   |
| Recurrence of pneumonia            | 4 (5.6%)                | 3 (3.2%)                   | 0.700   |
| Complications and adverse effects   |                         |                            |         |
| Complicated pleural effusion       | 1 (1.4%)                | 2 (2.2%)                   | 1.000   |
| CDAD                               | 3 (4.2%)                | 0 (0.0%)                   | 0.081   |
| Cardiac events                     | 4 (5.6%)                | 4 (4.3%)                   | 0.730   |
| Others                             | 8 (11.4%)               | 7 (7.5%)                   | 0.394   |

Data are expressed as number (%) of patients or median (IQR)

*aWithin 90 days

*bCardiac events included arrhythmia, heart failure, and myocardial infarction

*cOthers included diarrhea, gastrointestinal bleeding, pneumothorax, epilepsy, and back pain

Abbreviations: CDAD *Clostridium difficile*-associated diarrhea, IQR interquartile range
Cancer patients are at high risk for adverse drug reactions such as gastrointestinal and cardiogenic toxicity. In addition, cancer patients are more likely to be colonized with multi-drug resistant organisms with exposure to antibiotics. These problems can be overcome without the use of unnecessary antibiotics. This study showed that the rate of atypical pathogens was low although not all patients were examined. β-lactam monotherapy was not associated with 30- and 90-day mortality in the multivariate analysis. Rather, predictable variables such as duration of neutropenia, CRP level, and MASCC risk index were associated with mortality in neutropenic pneumonia. This result may support the fact that monotherapy is sufficient in non-critically ill patients with neutropenic pneumonia.

Due to the extended study period of 20 years, there were considerable differences in the types of β-lactams between the two groups. The preferred regimen for neutropenic pneumonia at our center was changed from ceftazidime combined with tobramycin to cefepime after 2002 due to increasing ceftazidime-resistance [27]. Instead of a tobramycin combination, clinicians tended to select either a macrolide or fluoroquinolone combinations to cover atypical pathogens in neutropenic pneumonia. As these changes in preferred regimens depending on the period may have introduced some bias, we performed a subgroup analysis of cefepime-treated patients to overcome this limitation. Second, as a limitation of retrospective studies, certain criteria have not been applied to the selection of the antibiotics, and the test results for diagnosis of pneumonia. Finally, screening for atypical pathogens was not performed in all patients and the Legionella test in this study covered only serotype 1. This is also the limitation of retrospective study, and efforts to find causative organisms of pneumonia through the tests including urinary antigen detection, respiratory virus PCR panels, sputum cultures are needed. Additional prospective studies are needed to modify this limitation.

In conclusion, this study revealed no differences in 30- and 90-day mortality between β-lactam monotherapy and combination therapy in cancer patients with non-severe community-onset neutropenic pneumonia. Monotherapy can reduce the chance of unwanted drug adverse reactions and acquisition of antibiotic resistance. Unnecessary combination therapy should be reconsidered in neutropenic pneumonia. Future studies are needed with better evaluations for atypical pathogens.

**Table 4** Multivariate analysis of 30-day all-cause mortality due to neutropenic pneumonia

| Variables                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | HR (95% CI)         | P-value               | HR (95% CI) | P-value |
| Lung cancer                | 3.55 (1.13–11.15)   | 0.030                 | 1.60 (0.30–8.63) | 0.586               |
| Palliative setting         | 4.83 (1.09–21.43)   | 0.038                 | 58.61 (0.26–13,356.90) | 0.142               |
| Duration of neutropenia    | 1.08 (1.03–1.15)    | 0.003                 | 1.27 (1.05–1.53) | 0.013               |
| CRP                        | 1.04 (1.00–1.08)    | 0.035                 | 1.06 (1.00–1.11) | 0.021               |
| MASCC risk index           | 0.68 (0.68–0.95)    | 0.010                 | 0.80 (0.65–0.99) | 0.042               |
| Combination therapy        | 0.27 (0.09–0.85)    | 0.025                 | 0.85 (0.20–3.67) | 0.827               |
| Types of β-lactams         |                     |                       |             |                    |
| Cefepime                   | 0.28 (0.10–0.81)    | 0.119                 | 0.64 (0.17–2.46) | 0.518               |
| Ceftazidime                | 2.05 (0.58–7.25)    | 0.268                 | 1.42 (0.40–5.02) | 0.589               |
| Piperacillin-tazobactam    | 5.95 (1.89–18.70)   | 0.002                 | 0.28 (0.01–50.00) | 0.631               |

**Additional files**

**Additional file 1:** Table S1. Causative pathogens of neutropenic pneumonia. (DOCX 15 kb)

**Additional file 2:** Table S2. Multivariate analysis of 90-day all-cause mortality due to neutropenic pneumonia. (DOCX 15 kb)

**Abbreviations**

CAP: Community-acquired pneumonia; CI: Confidence interval; CRP: C-reactive protein; HR: Hazard ratio; MASCC: Multinational Association for Supportive Care in Cancer

**Authors’ contributions**

All authors have read and approved the manuscript. The authors were solely responsible for the conception and performance of the study and for writing.
